KRAS and colorectal cancer: In a study conducted in 2012, where 252 patients with colorectal cancer and 293 subjects with negative results from colonoscopy were screened, Cologuard (KRAS mutation + fecal hemoglobin + NDRG4 and BMP3 methylation) exhibited a sensitivity of 85% and specificity of 90% (Ahlquist et al., 2012).